HBx Sensitizes Hepatocellular Carcinoma Cells to Lapatinib by Up-regulating ErbB3

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Nov 24

PMID 26595522

Citations 14

Authors

Jhen-Yu Chen

Yun-Ju Chen

Chia-Jui Yen

Wen-Shu Chen

Wei-Chien Huang

Affiliations

Soon will be listed here.

Abstract

Poor prognosis of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) involves HBV X protein (HBx)-induced tumor progression. HBx also contributes to chemo-resistance via inducing the expressions of anti-apoptosis and multiple drug resistance genes. However, the impact of HBx expression on the therapeutic efficacy of various receptor tyrosine kinase inhibitors remains unknown. In this study, our data showed that HBx overexpression did not alter the cellular sensitivity of HCC cell lines to sorafenib but unexpectedly enhanced the cell death induced by EGFR family inhibitors, including gefitinib, erlotinib, and lapatinib due to ErbB3 up-regulation. Mechanistically, HBx transcriptionally up-regulates ErbB3 expression in a NF-κB dependent manner. In addition, HBx also physically interacts with ErbB2 and ErbB3 proteins and enhances the formation of ErbB2/ErbB3 heterodimeric complex. The cell viability of HBx-overexpressing cells was decreased by silencing ErbB3 expression, further revealing the pivotal role of ErbB3 in HBx-mediated cell survival. Our data suggest that HBx shifts the oncogenic addiction of HCC cells to ErbB2/ErbB3 signaling pathway via inducing ErbB3 expression and thereby enhances their sensitivity to EGFR/ErbB2 inhibitors.

Citing Articles

Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets.

Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium Cancers (Basel). 2024; 16(5).

PMID: 38473265 PMC: 10931414. DOI: 10.3390/cancers16050901.

Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma.

Elmas A, Lujambio A, Huang K Front Oncol. 2022; 12:814120.

PMID: 35433463 PMC: 9006883. DOI: 10.3389/fonc.2022.814120.

HBxAg promotes HBV replication and EGFR activation in human placental trophoblasts.

Lin Y, Liu Y, Xu D, Guo F, Zhang W, Zhang Y Exp Ther Med. 2021; 22(5):1211.

PMID: 34584556 PMC: 8422389. DOI: 10.3892/etm.2021.10645.

Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2.

Wang B, Huang C, Liu L, Cheng F, Wei Y, Lin Y Front Pharmacol. 2021; 12:614673.

PMID: 34267653 PMC: 8276059. DOI: 10.3389/fphar.2021.614673.

Structural and functional analyses of hepatitis B virus X protein BH3-like domain and Bcl-xL interaction.

Zhang T, Chen H, Cao J, Xiong H, Mo X, Li T Nat Commun. 2019; 10(1):3192.

PMID: 31324803 PMC: 6642116. DOI: 10.1038/s41467-019-11173-1.

References

Lim K, Choi H, Park Y, Park E, Shin G, Kim D . HBx-induced NF-κB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS One. 2013; 8(3):e57331. PMC: 3587578. DOI: 10.1371/journal.pone.0057331. View

Chen K, Chen H, Tai W, Feng W, Hsu C, Chen P . Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011; 337(1):155-61. DOI: 10.1124/jpet.110.175786. View

Dhar D, Naora H, Yamanoi A, Ono T, Kohno H, Otani H . Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res. 2002; 22(1A):379-86. View

Shi X, Zhang Y, Zhou X, Lu J, Guo Z, Huang P . Hepatitis B virus X protein regulates the mEZH2 promoter via the E2F1-binding site in AML12 cells. Chin J Cancer. 2011; 30(4):273-9. PMC: 4013354. DOI: 10.5732/cjc.010.10437. View

Shen Y, Hsu C, Cheng A . Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 2010; 45(8):794-807. DOI: 10.1007/s00535-010-0270-0. View

Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M . Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 2001; 61(21):7803-10. View

Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P . ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010; 29(40):5500-10. PMC: 4256946. DOI: 10.1038/onc.2010.289. View

Skelton M, ONeil B . Targeted therapies for hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008; 6(3):209-18. View

Shi Y, Ding Z, Zhou J, Hui B, Shi G, Ke A . Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011; 7(10):1159-72. DOI: 10.4161/auto.7.10.16818. View

10.

Wu H, Chen P, Lin M, Chen D . Temporal aspects of major viral transcript expression in Hep G2 cells transfected with cloned hepatitis B virus DNA: with emphasis on the X transcript. Virology. 1991; 185(2):644-51. DOI: 10.1016/0042-6822(91)90535-j. View

11.

Chen W, Yen C, Chen Y, Chen J, Wang L, Chiu S . miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. Oncotarget. 2015; 6(28):25962-74. PMC: 4694878. DOI: 10.18632/oncotarget.4504. View

12.

El-Rayes B, LoRusso P . Targeting the epidermal growth factor receptor. Br J Cancer. 2004; 91(3):418-24. PMC: 2409851. DOI: 10.1038/sj.bjc.6601921. View

13.

van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F . Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2012; 329(1):74-83. DOI: 10.1016/j.canlet.2012.10.021. View

14.

Herceg Z, Paliwal A . Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res. 2011; 727(3):55-61. DOI: 10.1016/j.mrrev.2011.04.001. View

15.

Huang W, Chen W, Chen Y, Wang L, Hsu S, Chen C . Hepatitis B virus X protein induces IKKα nuclear translocation via Akt-dependent phosphorylation to promote the motility of hepatocarcinoma cells. J Cell Physiol. 2011; 227(4):1446-54. DOI: 10.1002/jcp.22860. View

16.

ONeill F, Madden S, Aherne S, Clynes M, Crown J, Doolan P . Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. Mol Cancer. 2012; 11:41. PMC: 3439312. DOI: 10.1186/1476-4598-11-41. View

17.

Gazdar A . Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010; 29(1):37-48. PMC: 3387977. DOI: 10.1007/s10555-010-9201-z. View

18.

Hung C, Huang W, Pan H, Chien P, Lin C, Chen L . Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int. 2014; 2014:827415. PMC: 3955687. DOI: 10.1155/2014/827415. View

19.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

20.

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View